Cysteine modified antibody-drug conjugate and preparation method thereof
Inventors
Zhu, Yi • WANG, YIXI • Zhuo, Shi • Li, Jie • Chen, Lan • WAN, Weili • YU, Yongguo
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
By inserting cysteine (C) into a heavy chain and/or a light chain of a target antibody at specific insertion site, and performing a site-specific conjugation through a free thiol group (—SH) from the site-specific inserted cysteine and a linker conjugated with a highly potent small molecule cytotoxin, a cysteine modified antibody-drug conjugate with good homogeneity is provided. The specific insertion sites of cysteine are position 205 and/or position 206 (Kabat numbering scheme) of the light chain of the antibody, and/or position 439 (Kabat numbering scheme) of the heavy chain.
Core Innovation
The invention is directed to a cysteine modified antibody-cytotoxin conjugate comprising an antibody and a cytotoxin. The antibody comprises an inserted cysteine at a cysteine insertion site so that the antibody comprises a light chain amino acid sequence GLSSPCVTKSF (SEQ ID NO: 13), or a light chain amino acid sequence GLSSPVCTKSF (SEQ ID NO: 14), or a heavy chain amino acid sequence TQKSLSCLSPGK (SEQ ID NO: 15). The inserted cysteine contains a thiol group, and the cytotoxin is conjugated to the thiol group through a linker.
Cytotoxin payloads are conjugated to the thiol group via a linker, including MMAE, MMAF, PBD, SN-38, Dox, and derivatives. The constructs retain antigen affinity, because the cysteine insertion is defined by specific Kabat positions and corresponding amino acid sequence embodiments (SEQ ID NO: 13-15). Conjugates are formed between an antibody carrying an inserted cysteine thiol and a cytotoxin moiety connected through a linker.
A conjugate preparation workflow is described that uses antibody reduction to generate the free thiol associated with the inserted cysteine, followed by conjugation to a linker-drug payload containing a cytotoxin moiety, and removal of unconjugated payload. The workflow also includes oxidizing the reduced antibody to restore inter-chain disulfide bonds. Purification is described using cation exchange chromatography and ultrafiltration, with examples of conjugated payloads including mc-vc-PABOH and mc-vc-PAB-payloads such as mc-vc-PAB-MMAE, mc-vc-PAB-MMAF, mc-vc-PBD, mc-vc-PAB-DOX, and mc-vc-PAB-SN-38.
Claims Coverage
The independent claim covers a cysteine modified antibody-cytotoxin conjugate with an antibody containing a thiol-bearing inserted cysteine defined by specific light-chain or heavy-chain amino acid sequences (SEQ ID NO: 13-15), and a cytotoxin conjugated to that thiol through a linker. Dependent claims narrow and specify which chain sequence is used, specify example cytotoxin payloads, constrain a cytotoxin-to-antibody ratio, and recite a conjugate preparation workflow and purification operations.
Inserted cysteine thiol-containing antibody with specified light-chain or heavy-chain sequences
An antibody comprising an inserted cysteine at a cysteine insertion site such that the antibody comprises a light chain comprising GLSSPCVTKSF (SEQ ID NO: 13), or a light chain comprising GLSSPVCTKSF (SEQ ID NO: 14), or a heavy chain comprising TQKSLSCLSPGK (SEQ ID NO: 15), wherein the inserted cysteine comprises a thiol group.
Cytotoxin conjugated to the inserted cysteine thiol through a linker
A cytotoxin conjugated to the thiol group through a linker, forming a cysteine modified antibody-cytotoxin conjugate.
Specified cytotoxin payload set
The cytotoxin is selected from MMAE, MMAF, PBD, SN-38, Dox, or a derivative thereof.
Conjugate preparation with reduction, unshielding, oxidation, conjugation, and purification
A method preparing a cysteine-modified antibody-cytotoxin conjugate by reducing an antibody to unshield an inserted cysteine thiol, removing decoupled shielding group and reducing agent via cation exchange chromatography or ultrafiltration, oxidizing to restore inter-chain disulfide bonds, conjugating an mc-vc-PAB-payload containing a cytotoxin moiety to the free thiol, and removing unconjugated mc-vc-PAB-payload via cation exchange chromatography or ultrafiltration.
Cytotoxin-to-antibody ratio range of 1.6 to 2
The cytotoxin-to-antibody ratio is 1.6 to 2.
Overall, the claim set focuses on conjugation chemistry driven by an inserted cysteine thiol in a specifically defined antibody light-chain or heavy-chain sequence (SEQ ID NO: 13-15), coupled with cytotoxin/linker conjugation, optional restriction to named cytotoxins, an explicit cytotoxin-to-antibody ratio range, and a described workflow that includes reduction, unshielding, oxidation to restore inter-chain disulfide bonds, thiol-linker-drug conjugation, and purification steps.
Stated Advantages
Retention of antigen affinity is noted.
Documented Applications
No documented applications found
Interested in licensing this patent?